Aryl imidazole compound, preparation method thereof and prepared pharmaceutical product

By developing aryl imidazole compounds, the problem of limited effectiveness of existing neuroprotective agents in treating neurological diseases has been solved, and the effect of significantly improving the survival rate of nerve cells and reducing oxidative stress damage has been achieved, with potential treatment of Alzheim Application value of silent disease and stroke.

CN119039230AActive Publication Date: 2024-11-29HENAN UNIVERSITY

Patent Information

Application Number
CN202411145687.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-29
Estimated Expiration
2044-08-20

Smart Images

  • Figure CN119039230A_ABST
    Figure CN119039230A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, relates to a neuroprotective medicine, and particularly relates to an aryl imidazole compound, a preparation method thereof and a pharmaceutical product prepared from the aryl imidazole compound. The compound has a structure as shown in a general formula (I): # imgabs0 #; pharmacological experiment results provided by the invention show that the arylimidazole compound has a protection effect on nerve cells, inhibits intracellular oxidative stress and inflammatory injury induced by hypoxia and hypoglycemia, improves oxygen-glucose deprivation and the survival rate of ApoE4 gene overexpression cells, and can be applied to neurodegenerative diseases as a neuroprotective agent.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, relates to neuroprotective drugs, and particularly refers to an aryl imidazole compound and a preparation method thereof and a pharmaceutical product prepared therefrom. Background Art

[0002] Neurological diseases such as stroke and Alzheimer's disease (AD) impose a huge health burden on individuals and society.

[0003] Neuroprotective agents are an important means of treating acute ischemic stroke. They have the functions of protecting nerve cells, improving cerebral blood flow and restoring neurological function. They are also of great significance for the rehabilitation of patients with acute ischemic stroke.

[0004] Alzheimer's disease (AD) is a chronic neurodegenerative disease associated with aging. So far, the pathogenesis of AD is still not fully understood. Widely accepted hypotheses include abnormal metabolism of apolipoprotein E4 (ApoE4), excessive accumulation of amyloid β (Aβ), and neurofibrillary tangles formed by hyperphosphorylation of tau protein. In addition, oxidative stress, inflammation, abnormal glial cell function, and cholinergic neuron damage are also involved in the occurrence and development of AD. At present, since the cause of AD has not been fully elucidated, the treatment of AD is mainly symptomatic treatment. The therapeutic drugs mainly include cholinesterase inhibitors and glutamate receptor antagonists, as well as some neuroprotective agents. These drugs can only alleviate or delay the various symptoms that occur during the disease process.

[0005] Neuroprotectants are usually used to prevent or alleviate nerve cell damage and death caused by neurological diseases, trauma or injury, and promote brain cell survival and recovery of function. Their mechanism of action mainly includes reducing oxidative stress of nerve cells, inhibiting inflammatory response, improving energy metabolism, and enhancing cell self-repair ability. By protecting and supporting damaged nerve cells, neuroprotectants can alleviate symptoms and dysfunction of neurological diseases, help maintain normal nerve function, and improve patient prognosis.

[0006] The development of neuroprotectants can effectively prevent, delay or treat Alzheimer's disease, stroke, Parkinson's disease and other diseases, fill the current treatment gaps and meet the needs of patients and their families.

[0007] This study aims to prepare a new compound and use it for the protection of nerve cells. Summary of the invention

[0008] In order to solve the above technical problems, the present invention provides an aryl imidazole compound, a preparation method thereof and a pharmaceutical product prepared thereby.

[0009] The technical solution of the present invention is achieved in this way: An aryl imidazole compound, the structural formula of which is as follows: .

[0010] The preparation method of the above-mentioned aryl imidazole compounds has the following technical route: .

[0011] The preparation steps are: 2-Hydroxybenzaldehyde, 2,5-dimethoxyaniline, benzyl, ammonium acetate and acetic acid were sequentially added into the reaction flask, protected by N2, and stirred at 110°C for reaction. After the reaction of the raw materials was complete, the heating was stopped, methanol was added, and water was added dropwise under stirring until precipitation was produced. The mixture was cooled to room temperature, filtered, washed and dried to obtain a crude product. After vacuum rotary evaporation, a white solid powder was obtained by column chromatography, with a yield of 49.68% and a melting point of 131.5-132.7°C. HPLC purity: 97.73%.

[0012] In the above step (1), the molar ratio of 2-hydroxybenzaldehyde, 2,5-dimethoxyaniline and dibenzoyl is 3-5:5-7:3-5; based on 1 mmol of 2-hydroxybenzaldehyde, 5 mmol of ammonium acetate and 2.4 mL of acetic acid are added.

[0013] The temperature of the above-mentioned heating and stirring reaction is 110°C; the inert gas is N2.

[0014] The volume ratio of acetic acid to methanol is 10:3.

[0015] The pharmaceutically acceptable salt of the above-mentioned aryl imidazole compound is a salt formed with the following acids: one or more of phosphoric acid, carbonic acid, hydrochloric acid, sulfuric acid, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, pantothenic acid, succinic acid, tartaric acid or p-toluenesulfonic acid.

[0016] The present invention relates to the use of the aryl imidazole compounds and pharmaceutically acceptable salts thereof in the preparation of neuroprotective drugs.

[0017] The above neuroprotection refers to: ① Improve the survival rate of neurons induced by ischemia and hypoxia and reduce cell death.

[0018] ②Reduce the release of lactate dehydrogenase in nerve cells induced by ischemia and hypoxia, and alleviate nerve cell damage.

[0019] ③Inhibit the production of intracellular reactive oxygen species induced by ischemia and hypoxia, and reduce oxidative stress damage.

[0020] ④Anti-ischemia and hypoxia-induced intracellular oxidative stress and inflammatory response.

[0021] ⑤ Improve the vitality of neurons overexpressing the ApoE4 gene and increase cell survival rate.

[0022] The above-mentioned pharmaceutical composition is compounded with conventional auxiliary materials in the art to prepare a pharmaceutical preparation.

[0023] The above-mentioned pharmaceutical preparation is any one of tablets, capsules, pills, suppositories, soft capsules, oral solutions, suspensions, injections, sustained-release preparations, controlled-release preparations, sustained-release preparations and microsome drug delivery systems.

[0024] A medicine, food or health product with neuroprotective effect, characterized in that it contains any of the following products: ① the above-mentioned aryl imidazole compounds; ② the above-mentioned salts; ③ the above-mentioned pharmaceutical composition; ④The above-mentioned pharmaceutical preparations.

[0025] The present invention has the following beneficial effects: 1. The present application discloses an aryl imidazole compound having a structure shown in the general formula (I): ; The pharmacological experimental results provided by the present invention show that the aryl imidazole compounds have a protective effect on nerve cells, inhibit intracellular oxidative stress and inflammatory damage induced by hypoxia and glucose deprivation, improve the survival rate of oxygen-glucose deprived and ApoE4 gene overexpressing cells, and can be used as neuroprotective agents in neurodegenerative diseases.

[0026] 2. The treatment with the aromatic imidazole compounds of the present application can significantly increase the cell survival rate of HT22 induced by oxygen-glucose deprivation, improve the neuroprotective effect of cell damage, reduce the production of ROS in the HT22 cell model induced by hypoxia, alleviate oxidative stress damage, and significantly increase the cell survival rate reduced by Na2S2O4 combined with sugar-free Earles solution. It has certain anti-inflammatory and antioxidant effects. 32 μmol / L of compound B11 can improve the cell survival rate to the greatest extent. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0028] Figure 1 This is the hydrogen spectrum of the aryl imidazole compound B11.

[0029] Figure 2 This is the carbon spectrum of aryl imidazole compound B11.

[0030] Figure 3 This is the effect of compound B11 on the viability of HT22 cells.

[0031] Figure 4 This is to screen the time of OGD modeling of mouse hippocampal neuron HT22 cells induced by hypoxia culture (94% N2, 1% O2, 5% CO2); n=5, all data are mean ± SEM, *** p <0.001.

[0032] Figure 5 Effect of compound B11 on OGD-induced HT22 cell viability; all data are mean ± SEM, n=6, compared with Con, ### p <0.001; compared with OGD,* p <0.05,** p <0.01.

[0033] Figure 6 Effect of compound B11 on LDH release induced by OGD (physical method) in HT22 cells; all data are expressed as mean ± SEM, n=3, compared with Con, ### p <0.001; compared with OGD, ** p <0.01,*** p <0.001.

[0034] Figure 7 Effect of compound B11 on OGD-induced ROS in HT22 cells; all data are expressed as mean ± SEM, n=3, compared with Con, ### p <0.001; compared with OGD,* p <0.05,** p <0.01,*** p <0.001.

[0035] Figure 8 The antioxidant effect of compound B11 on OGD-induced HT22 cells; all data are expressed as mean ± SEM, n=4, compared with Con, ### p <0.001, # p <0.05; compared with OGD, * p <0.05,** p <0.01.

[0036] Fig. 9Screening of OGD cell model conditions induced by Na2S2O4 and Earles' solution; n = 5, all data are mean ± SEM, n = 5; * p <0.05,** p <0.01.

[0037] Fig.10 Effects of compound B11 on the viability of HT22 cells induced by Na2S2O4 and Earles' solution; all data are mean ± SEM, n = 5; compared with Con, # p <0.05; compared with OGD, ** p <0.01,*** p <0.001.

[0038] Fig.11 Effects of compound B11 on MDA and NO in HT22 cells induced by Na2S2O4 / Earles' solution; all data are mean ± SEM, n = 4; compared with Con, ## p <0.01,### p <0.001; compared with OGD,* p <0.05,** p <0.01.

[0039] Fig.12 To build ApoE Gene overexpression HT22 cells; A: Immunofluorescence detection ApoE Gene expression; B: ApoE protein representative image and protein quantification results. All data are mean ± SEM, n = 4; compared with the HT22 group, ** p <0.01.

[0040] Fig.13 The protective effect of compound B11 on HT22 cells overexpressing ApoE4 gene; A: the effect of B11 on cell survival rate in the high concentration range; B: the effect of B11 on cell survival rate in the low concentration range. All data are mean ± SEM, n = 5; compared with ApoE3, # p<0.05 and ## p<0.01; compared with ApoE4, * p<0.5, ** p<0.01. DETAILED DESCRIPTION

[0041] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0042] Unless otherwise specified, the experimental methods used in the following experimental examples are all conventional methods; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.

[0043] Example 1: Synthesis of aryl imidazole compound B11 The preparation method of the aryl imidazole compound B11 of this embodiment is: 2-Hydroxybenzaldehyde (500.00 mg, 4.10 mmol), 2,5-dimethoxyaniline (940.57 mg, 6.15mmol), dibenzoyl (861.94 mg, 4.10 mmol), ammonium acetate (1.58 g, 20.50 mmol) and acetic acid (10 mL) were put into a reaction flask in sequence. The mixture was stirred at 110°C under N2 protection. After 4 h, TLC (developing solvent PE:EA = 2:1) was used to monitor whether the reaction was complete. After the raw materials reacted completely, heating was stopped, methanol (3 mL) was added, and water was added dropwise with stirring until precipitation occurred. The mixture was cooled to room temperature, filtered, washed (MeOH:H2O=1:1), and dried to obtain a crude product. After vacuum rotary evaporation, column chromatography (PE:EA = 5:1) was performed to obtain 912.5 mg of a white solid powder, i.e., aryl imidazole compound B11, with a yield of 49.68% and a melting point of 131.5-132.7°C. HPLC purity: 97.73%.

[0044] The H NMR spectrum of the aryl imidazole compound B11 prepared in this example ( Figure 1 ) and carbon spectrum ( Figure 2 ): ESI-HRMS: calcd. for C 29 H 25 N2O3[M+H] + : 449.1860, found: 449.1873. 1 H NMR (300 MHz, Chloroform- d ) δ 13.69 (br, 1H), 7.63 (d, J = 7.7 Hz,2H), 7.36-7.19 (m, 9H), 7.13 (d, J= 8.1 Hz, 1H), 6.96 (dd, J = 9.1, 3.0 Hz, 1H),6.88 (d, J = 9.1 Hz, 1H), 6.79 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 3.0 Hz, 1H), 6.57(t, J = 7.6 Hz, 1H), 3.70 (s, 3H), 3.58 (s, 3H). 13 C NMR (75 MHz, Chloroform- d ) δ 158.41, 153.55, 149.68, 145.12,134.82, 133.32, 130.95, 130.57, 130.15, 129.86, 128.48, 128.32, 128.27,126.88, 126.84, 126.40, 125.08,118.06, 117.57, 116.25, 115.46, 113.50,113.22, 56.01, 55.92. Example 2: Synthesis of aryl imidazole compound B11 The preparation method of the aryl imidazole compound B11 of this embodiment is: 2-Hydroxybenzaldehyde (3 mmol), 2,5-dimethoxyaniline 5 mmol), dibenzoyl (3 mmol), ammonium acetate (15 mmol), and acetic acid (7.2 mL) were sequentially added to a reaction flask, and the mixture was stirred at 110°C under N2 protection. After 4 hours, TLC (developing solvent PE:EA = 2:1) was used to monitor whether the reaction was complete. After the reaction of the raw materials was complete, heating was stopped, methanol (3 mL) was added, and water was added dropwise under stirring until precipitation occurred. The mixture was cooled to room temperature, filtered, washed (MeOH:H2O=1:1), and dried to obtain a crude product. After vacuum rotary evaporation, column chromatography (PE:EA = 5:1) was performed to obtain 687.7 mg of a white solid powder, namely, aryl imidazole compound B11, with a yield of 48.87% and a melting point of 131.5-132.7°C. HPLC purity: 97.16%.

[0045] The NMR data of the aryl imidazole compound B11 prepared in this example are as follows: ESI-HRMS: calcd. for C 29 H 25 N2O3[M+H] +: 449.1860, found: 449.1873. 1 H NMR (300 MHz, Chloroform- d ) δ 13.69 (br, 1H), 7.63 (d, J = 7.7 Hz,2H), 7.36-7.19 (m, 9H), 7.13 (d, J = 8.1 Hz, 1H), 6.96 (dd, J = 9.1, 3.0 Hz, 1H),6.88 (d, J = 9.1 Hz, 1H), 6.79 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 3.0 Hz, 1H), 6.57(t, J = 7.6 Hz, 1H), 3.70 (s, 3H), 3.58 (s, 3H). 13 C NMR (75 MHz, Chloroform- d ) δ 158.41, 153.55, 149.68, 145.12,134.82, 133.32, 130.95, 130.57, 130.15, 129.86, 128.48, 128.32, 128.27,126.88, 126.84, 126.40, 125.08,118.06, 117.57, 116.25, 115.46, 113.50,113.22, 56.01, 55.92. Example 3: Synthesis of aryl imidazole compound B11 The preparation method of the aryl imidazole compound B11 of this embodiment is: 2-Hydroxybenzaldehyde (5 mmol), 2,5-dimethoxyaniline (5 mmol), dibenzoyl (5 mmol), ammonium acetate (25 mmol), and acetic acid (12 mL) were sequentially added to a reaction flask, and the mixture was stirred at 110°C under N2 protection. After 4 hours, TLC (developing solvent PE:EA = 2:1) was used to monitor whether the reaction was complete. After the reaction of the raw materials was complete, heating was stopped, methanol (3 mL) was added, and water was added dropwise under stirring until precipitation occurred. The mixture was cooled to room temperature, filtered, washed (MeOH:H2O=1:1), and dried to obtain a crude product. After vacuum rotary evaporation and column chromatography (PE:EA = 5:1), 841.5 mg of a white solid powder was obtained, namely, aryl imidazole compound B11, with a yield of 49.02% and a melting point of 131.5-132.7°C. HPLC purity: 96.63%.

[0046] The NMR data of the aryl imidazole compound B11 prepared in this example are as follows: ESI-HRMS: calcd. for C 29 H 25 N2O3[M+H] + : 449.1860, found: 449.1873. 1 H NMR (300 MHz, Chloroform- d ) δ 13.69 (br, 1H), 7.63 (d, J = 7.7 Hz,2H), 7.36-7.19 (m, 9H), 7.13 (d, J = 8.1 Hz, 1H), 6.96 (dd, J = 9.1, 3.0 Hz, 1H),6.88 (d, J = 9.1 Hz, 1H), 6.79 (d, J = 8.0 Hz, 1H), 6.75 (d, J = 3.0 Hz, 1H), 6.57(t, J = 7.6 Hz, 1H), 3.70 (s, 3H), 3.58 (s, 3H). 13 C NMR (75 MHz, Chloroform- d) δ 158.41, 153.55, 149.68, 145.12,134.82, 133.32, 130.95, 130.57, 130.15, 129.86, 128.48, 128.32, 128.27,126.88, 126.84, 126.40, 125.08,118.06, 117.57, 116.25, 115.46, 113.50,113.22, 56.01, 55.92. Implementation effect example: The efficacy of B11 prepared in Example 1 was tested: First, the effect of B11 on the viability of normal mouse hippocampal neuronal cells HT22 cells was detected by MTT method to evaluate the toxicity of B11. Then, the protective effect of B11 on HT22 cells was tested in oxygen-glucose deprivation and ApoE4 transfected cell models.

[0047] 1. Effect of B11 on the viability of normal HT22 cells 1. Experimental methods HT22 cells in the logarithmic growth phase were selected for 96-well seeding, with 5000 cells / well and 100 μL DMEM per well, and cultured in a 37°C, 5% CO2 incubator. After 24 h, the control group was treated with 0.5% DMEM, and the drug-treated group was treated with different concentrations (2.5, 5, 10, 20, 40, 80, 160, 320 μmol / L) of B11. After 24 h, 10 μL of MTT was added to each well under light-proof conditions, and the cells were incubated in a 37°C oven for 1 h. After that, the OD value was measured at 570 nm with an enzyme reader for data processing.

[0048] , Experimental results The results are as follows Figure 3 The results showed that within the concentration range of 320 μmol / L, B11 had no significant effect on the survival rate of HT22 cells. The above results indicate that B11 has low cytotoxicity and high safety.

[0049] 2. Neuroprotective effect of B11 in oxygen-glucose deprivation cell model Ischemia-hypoxia injury is the basic pathological process of ischemic cerebrovascular disease. In vitro cell culture is an important method of scientific research. Oxygen glucose deprivation (OGD) is a stimulation model that simulates ischemia / hypoxia at the cellular level. By changing the cell culture conditions, including placing cells in a hypoxic box and replacing the culture medium without sugar, the damage of cells under ischemia / hypoxia is simulated, and the cells will produce necrosis, apoptosis and other phenomena, which are used for pathological or pharmacological research such as ischemic stroke.

[0050] This part of the experiment constructed an oxygen-glucose deprivation cell model to simulate the cell damage of ischemic stroke and test the protective effect of B11 on nerve cells.

[0051] Neuroprotective effect of B11 in OGD cell model constructed by physical method (1) Determination of model conditions In this part of the experiment, hypoxia-induced culture of mouse hippocampal neuron HT22 cells was used to construct an oxygen-glucose deprivation (OGD) cell model.

[0052] Experimental method: HT22 cells in logarithmic growth phase were plated in 96-well plates, with 5000 cells / well and 100 μL per well. The experimental groups were set as control group and model group, and cultured in a 37°C, 5% CO2 incubator for 24 h. After 24 h, the model group was replaced with sugar-free DMEM medium and placed in a hypoxic incubator (5% CO2, 1% O2, 94% N2) for OGD treatment. The cells were taken out of the incubator at 2, 4, 6, and 8 h, respectively, and the cell viability was detected by MTT method.

[0053] According to the experimental results, Figure 4 As shown, the modeling time point of 4 h of hypoxia (cell survival rate of about 50%) was finally selected for subsequent experiments.

[0054] (2) Effect of B11 on the survival rate of HT22 cells induced by OGD Experimental methods: HT22 cells in the logarithmic growth phase were plated in 96-well plates, with 5000 cells / well and 100 μL per well. The experimental groups were set as control group, model group and drug-treated group, and cultured at 37°C and 5% CO2 for 24 h. After 24 h, the control group and model group were treated with 0.5% DMEM medium, and the drug-treated group was treated with different concentrations (6.25, 12.5, 25, 50, 100 μmol / L) of drug-containing medium, and continued to be cultured in the incubator for 24 h. After that, the model was established, the model group was replaced with sugar-free DMEM medium, and the drug-treated group was given different concentrations of drug-free sugar medium, and placed in a hypoxic incubator (5% CO2, 1% O2, 94% N2) for OGD treatment for 4 h, and then the MMT method was used to detect the effect of compound B11 on cell survival rate.

[0055] The results show that ( Figure 5 ), pretreatment with B11 at concentrations of 12.5, 25, and 50 μmol / L could significantly increase the cell survival rate of HT22 cells induced by oxygen-glucose deprivation.

[0056] (3) Effect of B11 on LDH release in HT22 cells treated with OGD Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme widely present in various organisms. It cannot pass through the cell membrane under normal circumstances. It can be released outside the cell when the cell is damaged or dead. The released LDH is in the culture medium supernatant. Therefore, the degree of cell damage can be reflected by detecting the release of intracellular LDH.

[0057] Experimental methods: HT22 cells in the logarithmic growth phase were selected for 96-well plate seeding, with 5000 cells / well and 100 μl DMEM per well. The control group, model group, and drug-treated group were set up and placed in a 37°C, 5% CO2 incubator for 24 h. After 24 h, the control group and model group were treated with 0.5% DMEM medium, and the drug-treated group was given different concentrations of compound B11 (12.5, 25, 50 μmol / l) and placed in the incubator for further 24 h. After 24 h, the model group was replaced with sugar-free DMEM medium, and the drug-treated group was given different concentrations of drug-free sugar medium, and placed in a hypoxic incubator (5% CO2, 1% O2, 94% N2) for OGD treatment for 4 h. After the OGD treatment, the supernatant of the cell culture fluid of each group was collected, and the LDH level was detected according to the Elabscience LDH kit.

[0058] The experimental results showed that B11 (12.5, 25, 50 μmol / L) pretreatment significantly reduced the content of intracellular LDH induced by OGD, with significant differences. Figure 6 The experimental results show that compound B11 has a neuroprotective effect in improving cell damage.

[0059] (4) Effect of B11 on reactive oxygen species (ROS) levels in HT22 cells treated with OGD Experimental method: DCFH-DA fluorescent probe was used to detect the content of intracellular ROS. HT22 cells in the logarithmic growth phase were taken and the density of the digested cell suspension was adjusted to 1×10 5cells / mL, and inoculated into 6-well cell culture plates, 2 ml of cell suspension per well, and 3 parallel wells were set for each group. Cells in each group were treated for 24 h. After 24 h, the cells were pre-treated with medication. The control group and the model group were treated with 0.5% DMEM medium. The medication group was treated with different concentrations of compound B11 (12.5, 25, 50 μmol / L) and placed in the incubator for further culture for 24 h. After 24 h, the model and medication groups were modeled. The model group was replaced with sugar-free DMEM medium, and the medication group was treated with different concentrations of drug-containing sugar-free medium and placed in a hypoxic incubator (5% CO2, 1% O2, 94% N2) for OGD treatment for 4 h. After the OGD treatment, the culture medium was aspirated, the cells were washed three times with serum-free cell culture medium, and DCFH-DA was diluted with serum-free culture medium at 1:1000 to a final concentration of 10 mM and added to the 6-well plate. Incubate in a cell culture incubator at 37°C, 5% CO2 for 20 min. Invert and mix every 3-5 min to ensure full contact between the probe and the cells. Wash the cells three times with serum-free cell culture medium to fully remove the DCFH-DA that has not entered the cells. Adjust the microplate reader to 488 nm excitation wavelength and 525 nm emission wavelength to detect the fluorescence intensity of each group.

[0060] The experimental results show that ( Figure 7 ): Compared with the control group, OGD treatment significantly increased the ROS content in HT22 cells, as shown by the enhanced green fluorescence intensity. After treatment with different concentrations of B11 (12.5, 25, 50 μmol / L), the green fluorescence intensity was significantly weakened, and the ROS content in the cells decreased significantly, among which the 25 μmol / L dose group had the best effect. The above results show that B11 can reduce the production of ROS in the HT22 cell model induced by hypoxia and alleviate oxidative stress damage.

[0061] (5) Antioxidant effect of B11 on OGD-treated HT22 cells Oxidative stress produces a large amount of oxygen free radicals, causing DNA damage, which in turn causes varying degrees of cytotoxicity and tissue cell damage. Next, the content of lipid peroxide MDA, reduced glutathione GSH, and superoxide dismutase SOD levels were detected to evaluate the antioxidant effect of B11 on HT22 cells.

[0062] Experimental methods: MDA detection method: take no less than 3×10 6 cells, discard the cell culture supernatant, scrape the cells with a cell scraper, transfer the cells to a plastic centrifuge tube with a pipette, add 0.5 mL of reagent V extraction solution, mix for 2 minutes, break the cells into a suspension, and operate according to the MDA kit operation table.

[0063] GSH content detection: take 10 6 The cells were homogenized by adding 300-500 μL PBS (0.01 M, pH 7.4) or physiological saline (0.9% NaCl). After homogenization, centrifuge at 4°C, 10,000 × g for 10 min, and place the supernatant on ice for testing. The GSH detection kit was then used to vibrate the plate for 1 min, and then allowed to stand at room temperature for 5 min. The OD value was measured by the microplate reader at 450 nm.

[0064] Detection of SOD levels: absorb the supernatant from adherent cells, scrape the cells with a cell scraper, gently blow with a micropipette, aspirate all the liquid into an EP tube, then centrifuge at 1000 rpm for 10 minutes, discard the supernatant, keep the precipitated cells, add 1 ml PBS and gently blow, centrifuge at 1000 rpm again for 10 minutes, discard the supernatant, and keep the precipitated cells for later use. Add a certain amount of PBS to the cell precipitate, vortex and grind in an ice bath for 3 minutes for testing.

[0065] The experimental results show that ( Figure 8 ): Compared with the control group, the MDA content in the OGD group increased, and the GSH and SOD contents decreased significantly. After pretreatment with B11 (12.5, 25, 50 μmol / L), the above trend was reversed, among which 25 μmol / L B11 showed obvious effects in reducing the MDA content and increasing GSH and SOD. The above results show that B11 has a significant anti-oxidative stress effect.

[0066] Neuroprotective effect of B11 in OGD cell model constructed by chemical method (1) Determination of model conditions HT22 cells in the logarithmic growth phase were selected for 96-well plate seeding, with 5000 cells / well and 100 μL DMEM per well. The control group and model group were set up and placed in a 37°C, 5% CO2 incubator for 24 h. After 24 h, the model was established. The original culture medium was discarded in the control group and a new 0.5% DMEM culture medium was added; the original culture medium was discarded in the model group, and Na2S2O4 solution diluted with sugar-free Earles' solution was given at concentrations of 0.5mmol / L, 1 mmol / L, 2 mmol / L, 4mmol / L, 8 mmol / L, and 16 mmol / L, respectively, and placed in the incubator for 80 min. Afterwards, the 96-well plate was taken out of the incubator, and 10 μL of MTT was added to each well under light-proof conditions. The OD value was measured at 570 nm with an enzyme reader for data processing.

[0067] The results are as follows Fig. 9The results showed that compared with the control group, treatment with 4 mmol / L Na2S2O4 could reduce the cell survival rate to about 50%. Therefore, 4 mmol / L Na2S2O4 plus sugar-free Earles solution were finally selected as the chemical OGD model condition for 80 minutes in an incubator at 37°C and 5% CO2.

[0068] (2) B11 improves the survival rate of HT22 cells induced by Na2S2O4 / Earles' solution Experimental method: HT22 cells in the logarithmic growth phase were selected for 96-well plate seeding, with 5000 cells / well and 100 μl DMEM per well. The control group, model group and drug-treated group were set up and placed in a 37°C, 5% CO2 incubator for 24 h. After 24 h, the cells were pre-treated with drug administration, the control group and model group were treated with 0.5% DMEM, and the drug-treated group was treated with different concentrations of B11 (1, 3, 10, 30, 100 μmol / l), and the culture was continued in the incubator for 24 h. After 24 h, the model group and drug-treated group were modeled, and after the modeling was completed, the cell viability was measured by MTT method.

[0069] The experimental results showed that pretreatment with different concentrations of B11 could significantly increase the cell survival rate reduced by Na2S2O4 combined with sugar-free Earles solution ( Fig.10 ).

[0070] (3) B11 reduces the levels of MDA and NO in HT22 cells induced by Na2S2O4 Next, enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of lipid peroxide (MDA) and nitric oxide (NO) in HT22 cells treated with OGD.

[0071] Experimental method: HT22 cells in the logarithmic growth phase were selected for 96-well seeding, with 5000 cells / well and 100 μl DMEM per well. The control group, model group and drug-treated group were set up and placed in a 37°C, 5% CO2 incubator for 24 hours. After 24 hours, the cells were pre-treated with drug administration, the control group and the model group were treated with 0.5% DMEM replacement, and the drug-treated group was given different concentrations of compound B11 (3, 10, 30 μmol / l) and placed in the incubator for further 24 hours. After 24 hours, the model group and the drug-treated group were modeled. After the modeling was completed, the supernatant of the cell culture fluid and the cell pellet of each group were collected and operated according to the Elabscience MDA kit and Nanjing Jiancheng NO kit, respectively.

[0072] The results show that ( Fig.11): Compared with the control group, the contents of MDA and NO in HT22 cells induced by Na2S2O4 and Earles' solution increased significantly, while the contents of MDA and NO decreased significantly after intervention with different concentrations of B11 (3, 10, 30 μmol / L). The above results indicate that B11 has certain anti-inflammatory and antioxidant effects.

[0073] 3. Neuroprotective effect of B11 on HT22 cells transfected with ApoE4 gene In this part of the experiment, an ApoE transgenic cell model was constructed to examine the protective effect of B11 on HT22 cells overexpressing the ApoE4 gene.

[0074] , Construction of ApoE transgenic cell model (1) Packaging of lentivirus 1) Inoculate HEK-293FT cells in logarithmic growth phase into 6-well plates and wait for the cells to grow and become fused to about 50% of the lentiviral packaging; 2) Dilute 10 μL Lipo2000 and 4 μg total DNA (including ApoE4 / ApoE3 / NC, pSpax and PMD2G plasmids, mixed at a ratio of 2:2:1) with 250 μL serum-free and double antibody medium and let stand for 5 minutes; 3) Add the mixed plasmid solution to the culture medium containing Lip2000 serum-free and anti-double antibody, mix well, and let stand for 20 minutes; 4) Aspirate the old culture medium from the 6-well plate, add 1.5 mL of serum-free and anti-double antibody DMEM, and then add the previous mixed solution dropwise into the 6-well plate; 5) After 6-8 hours, replace the solution by removing the original medium and adding complete medium; 6) Collect the first virus after 24 hours: transfer the culture medium from the 6-well plate to a 15 mL centrifuge tube, set the centrifugation parameters to 1000 rpm, centrifuge for 5 minutes, centrifuge and package, freeze in a -80°C refrigerator, add 2 mL of culture medium to the 6-well plate again, and collect the virus again after 24 hours.

[0075] (2) Lentiviral transfection of target cells 1) Prepare HT22 cells, revive and subculture as described in 2.3. After subculture, seed the cells at a density of approximately 10 cells per well. 5 cells in a 6-well plate.

[0076] 2) When the cells grow and fuse to 60-80%, transfection is performed and the experiment is divided into control group, experimental group and infection group. The control group is the negative control lentivirus infection group (NC group), and the experimental group is the APOE3 lentivirus infection group and the APOE4 lentivirus infection group.

[0077] 3) Thaw the lentiviral solution from the -80℃ freezer, add 2μG / mL polybrene co-transfection reagent, blow and mix evenly, and let stand for 20 minutes.

[0078] 4) Discard the medium on the 6-well plate and replace it with 1 mL of complete medium. Then drop the suspension into the wells and place them in the incubator for culture.

[0079] 5) After 24 hours, observe the cell status and replace with 2 mL of complete medium before continuing the culture. After 48 hours, replace the complete medium containing μg / mL puromycin with 2 mL of complete medium to successfully kill the untransfected cells. After successful transfection, green fluorescence can be observed under a fluorescence microscope.

[0080] Experimental results: HT22 cells stably expressing ApoE gene were constructed using lentiviral transfection technology. The results were observed under an inverted fluorescence microscope. Fig.12 As shown in A, the transfection group showed strong green fluorescence because the plasmid vector contained a green fluorescent protein (GFP) tag. After 48 h of transfection, the cells were collected and the ApoE protein level in the cells was detected by Western blot. The results are shown in Fig.12 As shown in B, the ApoE protein in the transfection group was significantly higher than that in the blank control, indicating that the HT22 cell model with stable overexpression of ApoE3 and ApoE4 was successfully constructed and subsequent experiments can be carried out.

[0081] , B11 protective effect on ApoE4-HT22 cells The MTT method was used to examine the effect of B11 on the viability of HT22 cells overexpressing the ApoE4 gene.

[0082] Experimental method: Take cells in logarithmic growth phase and place them in 96-well plates, with 5000 cells / well and 100 μL per well, and culture them in a 37°C, 5% CO2 incubator. After 24 hours, the drug treatment was given. The next day, the 96-well plate was taken out of the incubator, and 10 μL of MTT was given to each well under light-proof conditions. The plates were incubated in a 37°C oven for 1 hour, and then the OD value was measured at 450nm with an enzyme marker for data processing.

[0083] Experimental results: ApoE3 cells were used as the control group, and ApoE4 overexpressed HT22 cells were used as the model group. Fig.13 As shown in A, after adding compound B11 at concentrations of 8, 16, 32, and 64 μmol / L in sequence, the survival rate of ApoE4 cells can be improved with the increase of drug concentration after adding compound B11 at concentrations of 8, 16, and 32 μmol / L, but the survival rate of cells is greatly inhibited after adding B11 at a concentration of 64 μmol / L.

[0084] In order to determine a more appropriate drug dose, ApoE3 cells were used as the control group and ApoE4-overexpressing HT22 cells were used as the model group, and B11 at a concentration below 32 μmol / L was selected to act on the cells. Fig.13 As can be seen from Figure B, overexpression of the ApoE4 gene can significantly reduce the survival rate of cells. After adding B11 at concentrations of 2, 4, 8, 16, and 32 μmol / L, the survival rate of cells can be improved as the gradient of drug concentration increases, indicating that B11 has a protective effect on HT22 cells with overexpression of the ApoE4 gene.

[0085] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. An aryl imidazole compound, the structural formula of which is as follows: .

2. The method for preparing the aryl imidazole compound according to claim 1, characterized in that: The steps are: (1) 2-hydroxybenzaldehyde, 2,5-dimethoxyaniline, dibenzoyl, ammonium acetate and acetic acid are sequentially placed in a reaction container, and heated and stirred under the protection of an inert gas until the reaction is complete to obtain a reaction liquid; (2) Stop heating the reaction solution of step (1), then add methanol, and then add water dropwise under stirring until precipitation occurs. After cooling to room temperature, the product is filtered, washed, and dried to obtain a crude product. After vacuum rotary evaporation, column chromatography is performed to obtain a white solid powder, i.e., an aryl imidazole compound.

3. The method for preparing an aryl imidazole compound according to claim 2, characterized in that: In the step (1), the molar ratio of 2-hydroxybenzaldehyde, 2,5-dimethoxyaniline and dibenzoyl is 3-5:5-7:3-5; based on 1 mmol of 2-hydroxybenzaldehyde, 5 mmol of ammonium acetate and 2.4 mL of acetic acid are added.

4. The method for preparing an aryl imidazole compound according to claim 3, characterized in that: The temperature of the heating and stirring reaction is 110°C; the inert gas is N2.

5. The method for preparing an aryl imidazole compound according to claim 3, characterized in that: The volume ratio of acetic acid to methanol is 10:

3.

6. The pharmaceutically acceptable salt of the aryl imidazole compound according to claim 1, characterized in that: The salt is a salt formed with the following acids: one or more of phosphoric acid, carbonic acid, hydrochloric acid, sulfuric acid, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, pantothenic acid, succinic acid, tartaric acid or p-toluenesulfonic acid.

7. A pharmaceutical composition, characterized in that: The invention comprises one or more of the aryl imidazole compound according to claim 1 or the salt according to claim 6, and a pharmaceutically acceptable carrier or excipient.

8. A pharmaceutical preparation prepared by compounding the pharmaceutical composition according to claim 7 with conventional excipients in the art.

9. The pharmaceutical preparation according to claim 8, characterized in that: The pharmaceutical preparation is any one of tablets, capsules, pills, suppositories, soft capsules, oral solutions, suspensions, injections, sustained-release preparations, controlled-release preparations, sustained-release preparations and microsome drug delivery systems.

10. A medicine, food or health product with neuroprotective effect, characterized in that: Products that include any of the following: ① The aryl imidazole compound according to claim 1; ② The salt according to claim 6; ③ The pharmaceutical composition according to claim 7; ④ The pharmaceutical preparation according to claim 8 or 9.

Citation Information

Patent Citations

  • Mitochondria-targeted neuroprotective drug TPP-QT, and preparation method and application thereof

    CN113527361A

  • Mechanism of inhibiting activity of p2x7 receptor on doparminergic neuronal cells

    KR1020080113845A

Cited By

  • A beta aggregation inhibitor as well as preparation method and application thereof

    CN121405635A